Fourier Rehab

Fourier Intelligence is a global leader in rehabilitation technology, specializing in developing and providing intelligent robotics solutions for individuals with motor disorders and neurological diseases. Founded in 2015, the company boasts a presence in over 50 countries and has installed over 900 units of rehabilitation equipment. Fourier's commitment to innovation is evident in its RehabHub™ product matrix, offering a comprehensive range of upper and lower extremity devices, as well as digital platforms for medical information and online interconnectivity.

Beyond rehabilitation, Fourier is also a general-purpose robot platform company, striving to transform various industries through intelligent technology. The company launched its first general-purpose bipedal robot, GR-1, in mid-2023, showcasing its capabilities in robotics beyond the medical field. With a vision to be the world's leading enabler of intelligent technologies for human well-being, Fourier Intelligence continues to push boundaries and redefine the possibilities of robotics.

Fourier Intelligence is a global leader in rehabilitation technology with a mission to empower human ability by developing and redefining rehabilitation robotics solutions with interconnectable intelligent robotics technology. Their goal is to make a difference in the lives of those with motor disorders and neurological diseases by providing high-performance rehabilitation robots and comprehensive solutions that improve their quality of life and help them regain their independence.

Fourier Intelligence fosters a culture of innovation, collaboration, and patient-centricity. The company's commitment to developing cutting-edge robotic solutions for rehabilitation is evident in its investment in research, partnerships with leading universities, and a strong focus on clinical outcomes. This translates into a workplace where employees are encouraged to think creatively, work together to solve complex problems, and ultimately make a positive impact on the lives of patients.